Publicaciones en las que colabora con MANUELA IGARTUA OLAECHEA (17)

2023

  1. Extracellular vesicles released by hair follicle and adipose mesenchymal stromal cells induce comparable neuroprotective and anti-inflammatory effects in primary neuronal and microglial cultures

    Cytotherapy, Vol. 25, Núm. 10, pp. 1027-1032

  2. Targeting the central nervous system: From synthetic nanoparticles to extracellular vesicles—Focus on Alzheimer's and Parkinson's disease

    Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, Vol. 15, Núm. 5

2022

  1. Dual effect of TAT functionalized DHAH lipid nanoparticles with neurotrophic factors in human BBB and microglia cultures

    Fluids and Barriers of the CNS, Vol. 19, Núm. 1

2021

  1. Polycaprolactone hybrid scaffolds combining 3D printing and electrospinning to guide the osteogenic differentiation of MC3T3 preosteoblasts for bone tissue regeneration

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 30-32

2020

  1. Nanostructured lipid carriers made of Ω-3 polyunsaturated fatty acids: In vitro evaluation of emerging nanocarriers to treat neurodegenerative diseases

    Pharmaceutics, Vol. 12, Núm. 10, pp. 1-22

2019

  1. Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation

    Neurobiology of Disease, Vol. 121, pp. 252-262

2018

  1. Análisis estadístico para realizar acciones de mejora en los Trabajos Fin de Grado. Una propuesta para el Grado en Farmacia

    REDU: Revista de Docencia Universitaria, Vol. 16, Núm. 2

  2. Intranasal administration of TAT-conjugated lipid nanocarriers loading GDNF for Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 145-155

  3. The role of lipid nanoparticles and its surface modification in reaching the brain: An approach for neurodegenerative diseases treatment

    Current Drug Delivery, Vol. 15, Núm. 9, pp. 1218-1220

2017

  1. Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors

    Molecular Neurobiology, Vol. 54, Núm. 10, pp. 7722-7735

  2. Nanotechnology based approaches for neurodegenerative disorders: Diagnosis and treatment

    Drug and Gene Delivery to the Central Nervous System for Neuroprotection: Nanotechnological Advances (Springer International Publishing), pp. 57-87

2016

  1. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases

    Nanomedicine, Vol. 11, Núm. 10, pp. 1267-1285

  2. Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson's disease

    Journal of Biomedical Nanotechnology, Vol. 12, Núm. 12, pp. 2220-2230

2015

  1. Competencias transversales en el Grado en Farmacia: una responsabilidad compartida para los equipos docentes

    Evaluación de la Calidad de la Investigación y de la Educación Superior: libro de resúmenes XI FECIES

  2. Topographical Distribution of Morphological Changes in a Partial Model of Parkinson’s Disease—Effects of Nanoencapsulated Neurotrophic Factors Administration

    Molecular Neurobiology, Vol. 52, Núm. 2, pp. 846-858

2014

  1. Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease

    International Journal of Nanomedicine, Vol. 9, Núm. 1, pp. 2677-2687

2013

  1. In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 85, Núm. 3 PART B, pp. 1183-1190